![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sanofi and GSK to Supply UK 60 Million Doses of COVID-19 Vaccine
Sanofi and GSK to Supply UK 60 Million Doses of COVID-19 Vaccine
July 30, 2020
Sanofi and GSK have reached an agreement with the UK government to supply 60 million doses of their COVID-19 vaccine. The financial details were not disclosed, and the contract must still be finalized.
The drugmakers teamed up in April to develop a vaccine using Sanofi’s recombinant protein-based vaccine technology and a GSK adjuvant.
Sanofi plans to begin a phase 1/2 trial of the vaccine in September, followed by a phase 3 study by the end of the year.
Upcoming Events
-
21Oct